Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Instil Bio Inc. (TIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: TIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $118.67
1 Year Target Price $118.67
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 248.31% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 86.50M USD | Price to earnings Ratio - | 1Y Target Price 118.67 |
Price to earnings Ratio - | 1Y Target Price 118.67 | ||
Volume (30-day avg) 4 | Beta 2.08 | 52 Weeks Range 10.80 - 42.79 | Updated Date 12/1/2025 |
52 Weeks Range 10.80 - 42.79 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.35 |
Earnings Date
Report Date 2025-11-13 | When - | Estimate -3.04 | Actual -1.75 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.91% | Return on Equity (TTM) -50.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 91788013 | Price to Sales(TTM) 55329.79 |
Enterprise Value 91788013 | Price to Sales(TTM) 55329.79 | ||
Enterprise Value to Revenue 43213.95 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 6781976 | Shares Floating 3228627 |
Shares Outstanding 6781976 | Shares Floating 3228627 | ||
Percent Insiders 6.29 | Percent Institutions 67.52 |
Upturn AI SWOT
Instil Bio Inc.
Company Overview
History and Background
Instil Bio Inc. is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer. Founded in 2018, they are pioneering TIL (Tumor-Infiltrating Lymphocyte) therapies.
Core Business Areas
- TIL Therapy Development: Focuses on developing and manufacturing TIL therapies for solid tumors.
Leadership and Structure
The leadership team includes key executives with experience in cell therapy and oncology. The organizational structure is typical of a clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- ITIL-168 (Lifileucel): An autologous TIL therapy in clinical development for advanced melanoma. It is currently in Phase 2. Competitors include Amgen (AMG) with Imlygic.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advances in immuno-oncology. Significant unmet need remains for effective solid tumor treatments.
Positioning
Instil Bio is positioned as a leader in TIL therapy, focusing on improving manufacturing and efficacy.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is estimated to reach billions of dollars. Instil Bio aims to capture a significant share through its TIL platform.
Upturn SWOT Analysis
Strengths
- Proprietary TIL therapy platform
- Clinical-stage assets
- Experienced management team
Weaknesses
- High cash burn
- Dependence on clinical trial success
- Manufacturing complexity
Opportunities
- Expansion to new cancer types
- Partnerships with larger pharmaceutical companies
- Advancements in TIL manufacturing
Threats
- Clinical trial failures
- Competition from other cell therapy approaches
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- BMY
- JNJ
- NK
Competitive Landscape
Instil Bio competes with larger pharmaceutical companies in the immuno-oncology space.
Growth Trajectory and Initiatives
Historical Growth: Limited revenue to date, growth dependent on clinical trial milestones.
Future Projections: Future growth is contingent on successful clinical trial results and regulatory approvals.
Recent Initiatives: Advancing clinical trials for ITIL-168.
Summary
Instil Bio is a high-risk, high-reward clinical-stage biotech company focused on TIL therapy. Its success hinges on the successful completion of clinical trials and regulatory approval. Its financial stability depends on continued funding. The company faces significant competition from established players in the immuno-oncology field.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Instil Bio Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-03-19 | Chairman & CEO Mr. Bronson Crouch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://instilbio.com |
Full time employees 14 | Website https://instilbio.com | ||
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.